SAN DIEGO, May 5, 2015 /PRNewswire/ — MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage oncology drug development company, announced today it has received the final report on toxicology testing of its HuMab 5B1 antibody, which was completed by a leading independent…


Source: PrNewwire

Related Posts Plugin for WordPress, Blogger...